Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - VCI Global Limited (VCIG) is up 57% at $2.79 [3] - The Beachbody Company, Inc. (BODI) is up 29% at $6.52 [3] - Cycurion, Inc. (CYCU) is up 29% at $3.41 [3] - BigBear.ai Holdings, Inc. (BBAI) is up 19% at $6.82 [3] - Hallador Energy Company (HNRG) is up 17% at $23.60 [3] - The RealReal, Inc. (REAL) is up 15% at $12.92 [3] - Galecto, Inc. (GLTO) is up 12% at $19.45 [3] - LivePerson, Inc. (LPSN) is up 12% at $5.87 [3] - Rocket Lab Corporation (RKLB) is up 9% at $56.80 [3] - Babcock & Wilcox Enterprises, Inc. (BW) is up 5% at $7.33 [3] Premarket Losers - Vor Biopharma Inc. (VOR) is down 31% at $12.81 [4] - Outset Medical, Inc. (OM) is down 27% at $8.81 [4] - Comtech Telecommunications Corp. (CMTL) is down 15% at $2.54 [4] - Laird Superfood, Inc. (LSF) is down 10% at $3.69 [4] - CoreWeave, Inc. (CRWV) is down 9% at $95.41 [4] - Gemini Space Station, Inc. (GEMI) is down 8% at $15.33 [4] - Precision BioSciences, Inc. (DTIL) is down 8% at $5.56 [4] - iOThree Limited (IOTR) is down 8% at $3.43 [4] - SenesTech, Inc. (SNES) is down 8% at $3.19 [4] - Life360, Inc. (LIF) is down 6% at $87.00 [4]

Core Insights - Celanese reported quarterly earnings of $1.34 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, but down from $2.44 per share a year ago, indicating an earnings surprise of +5.51% [1] - The company posted revenues of $2.42 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 1.69% and down from $2.65 billion year-over-year [2] - Celanese shares have declined approximately 46.6% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The future performance of Celanese's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - Current consensus EPS estimate for the upcoming quarter is $0.96 on revenues of $2.32 billion, and for the current fiscal year, it is $4.27 on revenues of $9.7 billion [7] Industry Context - The Chemical - Specialty industry, to which Celanese belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, which may negatively impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5][6]

Core Insights - Green Plains Renewable Energy (GPRE) reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, but down from $0.35 per share a year ago [1] - The earnings surprise was +250.00%, contrasting with a previous quarter's loss expectation of $0.28 per share, where the actual loss was $0.41, resulting in a surprise of -46.43% [2] - The company posted revenues of $508.49 million for the quarter, missing the Zacks Consensus Estimate by 8.08% and down from $658.73 million year-over-year [3] Financial Performance - Over the last four quarters, Green Plains has surpassed consensus EPS estimates only once [2] - The stock has gained approximately 5.7% since the beginning of the year, while the S&P 500 has increased by 15.1% [4] Future Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes [5] - The current consensus EPS estimate for the next quarter is $0.11 on revenues of $552.4 million, and for the current fiscal year, it is -$1.61 on revenues of $2.26 billion [8] Industry Context - The Chemical - Specialty industry, to which Green Plains belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, indicating potential challenges [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [6][7]

Core Insights - Linde reported quarterly earnings of $4.21 per share, exceeding the Zacks Consensus Estimate of $4.18 per share, and up from $3.94 per share a year ago, representing an earnings surprise of +0.72% [1] - The company achieved revenues of $8.62 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.17% and increasing from $8.36 billion year-over-year [2] - Linde has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Financial Performance - The earnings surprise for the previous quarter was +1.49%, with actual earnings of $4.09 per share compared to an expected $4.03 [1] - The current consensus EPS estimate for the upcoming quarter is $4.24, with expected revenues of $8.63 billion, and for the current fiscal year, the EPS estimate is $16.46 on revenues of $33.84 billion [7] Market Position - Linde shares have increased approximately 2.7% since the beginning of the year, while the S&P 500 has gained 16%, indicating underperformance relative to the broader market [3] - The Zacks Industry Rank for Chemical - Specialty is in the bottom 39% of over 250 Zacks industries, suggesting potential challenges for the sector [8] Future Outlook - The sustainability of Linde's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The trend of estimate revisions for Linde was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]

Company Overview - STRATA Skin Sciences, Inc. is a medical technology company focused on developing and commercializing products for dermatological conditions, utilizing expertise in laser technology [1] Financial Performance - STRATA's Return on Invested Capital (ROIC) is -58.59%, while its Weighted Average Cost of Capital (WACC) is 7.71%, resulting in a ROIC to WACC ratio of -7.60, indicating inefficiencies in capital utilization [2] - Comparatively, Sensus Healthcare, Inc. has a ROIC of -4.47% and a WACC of 10.28%, leading to a ROIC to WACC ratio of -0.44, which is the highest among its peers, suggesting better capital efficiency [3] - Other peers like Soleno Therapeutics, Inc. and SenesTech, Inc. have ROIC to WACC ratios of -13.40 and -12.05, respectively, indicating significant challenges in generating returns above their cost of capital [4] - Xcel Brands, Inc. also faces issues with a ROIC to WACC ratio of -8.94, highlighting inefficiencies in capital management [4] - Overall, all companies, including STRATA, are struggling to generate returns above their cost of capital, with Sensus Healthcare standing out for its relatively better performance [5]

Core Insights - SenesTech, Inc. is expanding the deployment of its Evolve™ Rat Birth Control in the Wicker Park Bucktown area of Chicago, aiming to manage rodent populations without harmful toxins [1][2] - The initiative is a collaboration between SenesTech and local commerce groups, highlighting a joint effort to address urban pest control challenges [5] - Recent media coverage has noted similar deployments in other urban areas, including a pilot program in New York City and initiatives in Boston and Baltimore [3] Company Overview - SenesTech focuses on humane pest management through fertility control, with products designed to integrate into existing pest management programs, enhancing effectiveness while reducing reliance on traditional poisons [6] - The company aims to create healthier environments and cleaner cities through its innovative solutions [6] Community Engagement - A dedicated informational website has been launched for residents and business owners in the Wicker Park Bucktown area to provide updates and information about the Evolve™ program [4] - Early reports on the consumption of Evolve™ Rat indicate positive feedback, and the company is preparing for further shipments as the deployment area expands [5]

Core Insights - SenesTech, Inc. is participating in a webcast fireside chat at the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025 [1][2] - The company focuses on humane fertility control solutions for managing rodent populations, aiming to create healthier environments [3] Company Overview - SenesTech's products, such as Evolve rodent birth control, enhance pest management programs while reducing reliance on traditional poisons [3] - The company's mission includes creating cleaner cities, more efficient businesses, and healthier communities through humane and sustainable products [3] Event Details - The fireside chat is scheduled for 3:00 p.m. ET on April 1, 2025, and will be accessible via the conference home page [2] - A replay of the chat will be available through the same links, and one-on-one investor meetings can be arranged upon request [2]

Core Viewpoint - SenesTech, Inc. has reported significant financial improvements in Q4 2024, including a 70% increase in revenue and a strategic focus on operating optimization initiatives aimed at reducing expenses by approximately $2 million annually to accelerate profitability [1][7][6]. Financial Performance - Revenue for Q4 2024 increased by 70% to $501,000 compared to $295,000 in Q4 2023, driven by a 206% growth in e-commerce [5]. - Gross profit margin improved to 60.9% in Q4 2024 from 43.7% in Q4 2023 [5]. - Operating expenses decreased by 16% in Q4 2024 compared to the same quarter in 2023 [5]. - Net loss for Q4 2024 was $1.3 million, an improvement from a net loss of $1.7 million in Q4 2023 [5]. - Adjusted EBITDA loss for Q4 2024 was $1.1 million, down from $1.6 million in Q4 2023 [5]. Key Growth Initiatives - The Evolve™ Rat product line became the largest revenue contributor, accounting for approximately 52% of Q4 2024 revenue [5]. - The Evolve™ Mouse product, launched in May 2024, contributed 24% of Q4 2024 revenue [5]. - The company has expanded its distribution through major online retailers, including Amazon and Walmart [5]. - Municipal programs for rodent contraception have been initiated in cities like New York, Baltimore, Chicago, and Boston [5]. - International distribution agreements have been signed in 10 countries, with product shipments already occurring in several regions [5]. Operating Optimization Initiatives - New initiatives are expected to reduce expenses by $2 million annually, lowering the revenue threshold for cash flow breakeven to approximately $7 million from a previous estimate of $12 million [6][8]. - The company aims to enhance operational efficiencies and streamline costs to accelerate its path to profitability [6][8]. Management Commentary - The CEO highlighted the transformational year for SenesTech, emphasizing strong financial results and the smallest quarterly Adjusted EBITDA loss in the company's history [7]. - The management is committed to a focused strategy that targets sustainable long-term success in the multi-billion-dollar rodent control market [8].

Core Viewpoint - SenesTech, Inc. has entered into definitive agreements for the immediate exercise of certain outstanding warrants, allowing the purchase of 374,718 shares at a reduced exercise price, aiming to raise capital for working and corporate purposes [1][3]. Group 1: Warrant Exercise and Financial Details - The existing warrants, originally priced at $4.35 per share, will now be exercised at $2.90 per share, generating approximately $1.1 million in gross proceeds before fees [1][3]. - New short-term warrants will be issued, potentially raising an additional $4.3 million if fully exercised [3][5]. - The new short-term warrants will allow the purchase of up to 1,498,872 shares at the same reduced price of $2.90 per share [5]. Group 2: Regulatory and Compliance Information - The resale of shares from the existing warrants has been registered under an effective registration statement [4]. - The new short-term warrants have not been registered under the Securities Act of 1933, meaning they cannot be sold in the U.S. without proper registration or exemption [6]. Group 3: Company Overview - SenesTech focuses on humane pest management solutions, particularly through its Evolve™ rodent birth control product, aiming to create healthier environments and reduce reliance on traditional poisons [8].

Core Viewpoint - SenesTech, Inc. will release its financial results for the fourth quarter and fiscal year 2024 on March 12, 2025, after market close, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - The financial results for the fourth quarter and fiscal year 2024 will be reported after market close on March 12, 2025 [1]. - A conference call is scheduled for the same day at 5:00 pm ET to review the financial results [1]. Group 2: Conference Call Details - Interested parties can join the conference call by dialing (844) 308-3351 or (412) 317-5407 [2]. - A live webcast of the conference call will be available on the Investor Relations section of the company's website [2]. Group 3: Replay Information - A teleconference replay will be available for seven days at (877) 344-7529 or (412) 317-0088, with a replay access code of 7759112 [3]. - A webcast replay will be accessible for 90 days in the Investor Relations section of the company's website [3]. Group 4: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, aiming to create healthier environments [4]. - The company's products, such as Evolve™ rodent birth control, enhance pest management effectiveness while reducing reliance on traditional poisons [4].